Ataraxis AI Launches Test to Predict Response to Neoadjuvant Therapy in Breast Cancer
The tool uses digitized pathology slides to estimate how patients will respond to therapy before surgery.
Category: Cancer
Cancer
Latest
Cancer
Latest
Blood Test Using Inflammatory Biomarkers Advances for Colorectal Cancer Detection
Irish researchers have secured €670,000 to clinically validate a blood-based colorectal cancer screening test using inflammatory biomarkers, aiming for launch by 2027 through a new spin-out company.
Cancer
Latest
Liquid Biopsy Technology Detects Over 95% of Early-Stage Cancers in Blinded Validation Study
A novel enrichment method produces virtually pure circulating tumor DNA from blood samples, showing strong sensitivity and specificity across colorectal and lung cancer patients.
HNL Lab Medicine Partners with Ibex to Bring AI Prostate Cancer Diagnostics to Its Labs
The Pennsylvania-based laboratory will integrate Ibex’s AI solution for prostate biopsies and TURP specimens into its existing digital pathology infrastructure.
Read More
Blood Test May Help Guide Breast Cancer Treatment Decisions in Women 70 and Older
Researchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
Read More
Precipio and Memorial Sloan-Kettering Publish Study on BCR::ABL1 Assay for Leukemia Monitoring
The Bloodhound BCR::ABL1 assay simultaneously detects and quantifies all four clinically important isoforms in a single run, offering new capabilities for chronic myeloid leukemia management.
Read More
Walgreens Partners to Expand Colorectal Cancer Screening Access
The initiative gives eligible pharmacy customers a streamlined pathway to request the Cologuard stool DNA test, with no prep or special diet required.
Read More
Hepion Pharmaceuticals Licenses ctRNA Biomarker Assay for Liver Cancer Detection
Hepion Pharmaceuticals has licensed a circulating tumor RNA assay from Cirna Diagnostics for early detection of hepatocellular carcinoma in high-risk patients, expanding its liquid biopsy portfolio for liver cancer.
Read More
Protein Biomarker Tests May Detect Cancer Earlier Than DNA-Based Methods
20/20 BioLabs argues a tiered screening approach—starting with protein-based tests before moving to circulating tumor DNA testing or imaging—could improve early-stage detection and lower costs.
Read More
Study Finds Multi-Omic Breast Cancer Test Predicts Radiation Therapy Benefit
Data show the test can predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Read More
Guardant’s Shield CRC Blood Test Now Orderable Through Quest Diagnostics Network
Physicians can now order the Shield blood test through Quest’s network of nearly 650,000 clinician and hospital accounts, patient service centers, and in-office phlebotomists.
Read More
Study Shows Dual Epigenetic Markers Improve Early Colorectal Cancer Detection
A study reports that dual epigenetic markers in cell-free DNA achieved 95% diagnostic accuracy for stage I colorectal cancer, outperforming conventional liquid biopsy methods.
Read More
FDA Grants Breakthrough Status to Breath Test for Postoperative Pneumonia Risk
The FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.’s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.
Read More
Fecal DNA Methylation Test Shows Promise for Colorectal Cancer Screening
A multicenter study reports that combining fecal SDC2 methylation testing with the APCS scoring system improves advanced adenoma detection and specificity in colorectal cancer screening.
Read More
Blood Test Could Enable Earlier Detection of Gallbladder Cancer
Researchers have identified blood-based metabolic signatures that may enable earlier, noninvasive detection of gallbladder cancer, according to findings in the Journal of Proteome Research.
Read More
Veracyte Presents 15 Studies on Decipher Cancer Tests at ASCO GU Symposium
Veracyte will present over 15 studies on its Decipher prostate and bladder cancer tests, including new clinical trial data, at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco.
Read More
NeoGenomics Launches PanTracer Pro for Solid Tumor Testing
The integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.
Read More
Three-Year NHS Study Shows Blood Test Reduces Stage IV Cancer Diagnoses
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
Read More
- 1
- ...
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- ...
- 193